Literature DB >> 26520562

Albumin and depression in elderly stroke survivors: An observational cohort study.

Michaela C Pascoe1, Ingmar Skoog2, Christian Blomstrand3, Thomas Linden4.   

Abstract

BACKGROUND/
OBJECTIVES: Post-stroke depression affects approximately one third of stroke survivors. In non-stroke affected populations, depressive symptomatology is associated with hypoalbuminemia. This is also common among stroke survivors and associated with poor outcome and increased mortality. The role of stroke-associated hypoalbuminemia in post-stroke depression is not clear. We aimed to explore the relationship between serum albumin and post-stroke depression, as measured 20 months post-stroke. SUBJECTS/
METHODS: Observational cohort study of elderly Swedish patients drawn from the 'Gothenburg 70+ Stroke Study' (n=149) and assessed at 20 months after stroke onset. Serum albumin was drawn from venous blood and analysed with gas chromatography/mass spectrometry. Depressive symptomatology was assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS) and functional impairment was assessed using the Barthel Index.
RESULTS: Analysis of covariance analysis showed that serum albumin levels were associated with depressive symptoms at 20 months after stroke. Multivariate analysis of covariance showed that disability scores at 3 days were associated with depressive symptoms at 20 months after stroke and after accounting for the age covariate. Stroke survivors were not clinically deficient in serum albumin.
CONCLUSIONS: Low serum albumin appears to be associated with depressive symptoms in elderly individuals long term post-stroke.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Depression; Old age; Outcome; Risk factors; Stroke

Mesh:

Substances:

Year:  2015        PMID: 26520562     DOI: 10.1016/j.psychres.2015.10.023

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  6 in total

1.  Potential use of albumin and neutrophil-to-lymphocyte ratio to guide the evaluation and treatment of cancer-related depression and anxiety.

Authors:  Daniel C McFarland; Allison J Applebaum; Erik Bengtsen; Yesne Alici; William Breitbart; Andrew H Miller; Christian Nelson
Journal:  Psychooncology       Date:  2021-09-04       Impact factor: 3.955

2.  Peripheral blood and urine metabolites and biological functions in post-stroke depression.

Authors:  Haiyan Liu; Juncai Pu; Qinxiang Zhou; Lining Yang; Dingqun Bai
Journal:  Metab Brain Dis       Date:  2022-04-19       Impact factor: 3.655

3.  New lung cancer treatments (immunotherapy and targeted therapies) and their associations with depression and other psychological side effects as compared to chemotherapy.

Authors:  Daniel C McFarland
Journal:  Gen Hosp Psychiatry       Date:  2019-04-18       Impact factor: 3.238

4.  Depression and Inflammation in Patients With Lung Cancer: A Comparative Analysis of Acute Phase Reactant Inflammatory Markers.

Authors:  Daniel C McFarland; William Breitbart; Andrew H Miller; Christian Nelson
Journal:  Psychosomatics       Date:  2020-04-02       Impact factor: 2.386

5.  Prognostic implications of depression and inflammation in patients with metastatic lung cancer.

Authors:  Daniel C McFarland; Rebecca M Saracino; Andrew H Miller; William Breitbart; Barry Rosenfeld; Christian Nelson
Journal:  Future Oncol       Date:  2020-12-11       Impact factor: 3.404

6.  The association between serum albumin and depression in chronic liver disease may differ by liver histology.

Authors:  Junyan Cao; Weihong Qiu; Yong Yu; Na Li; Huixiang Wu; Zhaocong Chen
Journal:  BMC Psychiatry       Date:  2022-01-04       Impact factor: 3.630

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.